Exploring how chromatin defects contribute to cancer development
A New Target for Chromatin Remodeler Defects in Cancer
['FUNDING_OTHER'] · BAYLOR COLLEGE OF MEDICINE · NIH-10911171
This study is looking at how problems with certain proteins in our cells can change our DNA and possibly increase the risk of cancer, especially when combined with environmental factors, and it hopes to find new ways to treat or prevent cancer that could help patients like you.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BAYLOR COLLEGE OF MEDICINE (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10911171 on ClinicalTrials.gov |
What this research studies
This research investigates the role of chromatin remodeler defects in cancer, focusing on how environmental factors can alter the epigenome and increase cancer risk. The approach involves studying the dual functions of chromatin remodelers, which not only modify epigenetic marks on DNA but also influence the cytoskeleton. By understanding these mechanisms, the research aims to uncover new targets for cancer treatment and prevention. Patients may benefit from insights that could lead to novel therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a history of cancer or those at high risk due to environmental exposures.
Not a fit: Patients with cancers unrelated to chromatin remodeler defects or those without significant environmental exposure history may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that target the underlying mechanisms of cancer related to chromatin defects.
How similar studies have performed: Previous research has shown promising results in understanding the role of epigenetics in cancer, suggesting that this approach could yield significant insights.
Where this research is happening
HOUSTON, UNITED STATES
- BAYLOR COLLEGE OF MEDICINE — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WALKER, CHERYL L. — BAYLOR COLLEGE OF MEDICINE
- Study coordinator: WALKER, CHERYL L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Suppressor Genes, Cancers